COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome
Introduction Guillain–Barré syndrome associated with Coronavirus-2-related severe acute respiratory syndrome (COV-GBS) occurs as para- or post-infectious forms, depending on the timing of disease onset. In these two forms, we aimed to compare the cerebrospinal fluid (CSF) and serum proinflammatory cytokine profiles to evaluate differences that could possibly have co-pathogenic relevance. Materials and methods We studied a retrospective cohort of 26 patients with either post-COV-GBS (n = 15), with disease onset occurring > 7 days after SARS-CoV-2 infection, or para-COV-GBS (n = 11), with disease onset 7 days or less. TNF-α, IL-6, and IL-8 were measured in the serum with SimplePlex™ Ella™ immunoassay. In addition to the para-/post-COV-GBS patients, serum levels of these cytokines were determined in those with non-COVID-associated-GBS (NC-GBS; n = 43), paucisymptomatic SARS-CoV-2 infection without GBS (COVID, n = 20), and in healthy volunteers (HV; n = 12). CSF cytokine levels were measured in patients with para-/post-COV-GBS, in those with NC-GBS (n = 29), or with Alzheimer’s disease (AD; n = 24). Results Serum/CSF cytokine levels did not differ in para- vs post-COV-GBS. We found that SARS-CoV-2 infection raises the serum levels of TNF-α, IL-6, and IL-8, as well as an increase of IL-6 (in serum and CSF) and IL-8 (in CSF) in either NC-GBS or COV-GBS than controls. CSF and serum cytokine levels resulted independent one with another. Conclusions The change of cytokines linked to SARS-CoV-2 in COV-GBS appears to be driven by viral infection, although it has unique characteristics in GBS as such and does not account for cases with para- or post-infectious onset..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Neurological sciences - 45(2024), 3 vom: 03. Jan., Seite 849-859 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Massa, Federico [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Fondazione Società Italiana di Neurologia 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10072-023-07279-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054707234 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054707234 | ||
| 003 | DE-627 | ||
| 005 | 20240210064644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10072-023-07279-6 |2 doi | |
| 035 | |a (DE-627)SPR054707234 | ||
| 035 | |a (SPR)s10072-023-07279-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Massa, Federico |e verfasserin |0 (orcid)0000-0001-5667-204X |4 aut | |
| 245 | 1 | 0 | |a COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Fondazione Società Italiana di Neurologia 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Introduction Guillain–Barré syndrome associated with Coronavirus-2-related severe acute respiratory syndrome (COV-GBS) occurs as para- or post-infectious forms, depending on the timing of disease onset. In these two forms, we aimed to compare the cerebrospinal fluid (CSF) and serum proinflammatory cytokine profiles to evaluate differences that could possibly have co-pathogenic relevance. Materials and methods We studied a retrospective cohort of 26 patients with either post-COV-GBS (n = 15), with disease onset occurring > 7 days after SARS-CoV-2 infection, or para-COV-GBS (n = 11), with disease onset 7 days or less. TNF-α, IL-6, and IL-8 were measured in the serum with SimplePlex™ Ella™ immunoassay. In addition to the para-/post-COV-GBS patients, serum levels of these cytokines were determined in those with non-COVID-associated-GBS (NC-GBS; n = 43), paucisymptomatic SARS-CoV-2 infection without GBS (COVID, n = 20), and in healthy volunteers (HV; n = 12). CSF cytokine levels were measured in patients with para-/post-COV-GBS, in those with NC-GBS (n = 29), or with Alzheimer’s disease (AD; n = 24). Results Serum/CSF cytokine levels did not differ in para- vs post-COV-GBS. We found that SARS-CoV-2 infection raises the serum levels of TNF-α, IL-6, and IL-8, as well as an increase of IL-6 (in serum and CSF) and IL-8 (in CSF) in either NC-GBS or COV-GBS than controls. CSF and serum cytokine levels resulted independent one with another. Conclusions The change of cytokines linked to SARS-CoV-2 in COV-GBS appears to be driven by viral infection, although it has unique characteristics in GBS as such and does not account for cases with para- or post-infectious onset. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Guillain–Barré syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytokines |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neuroinflammation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Vigo, Tiziana |4 aut | |
| 700 | 1 | |a Bellucci, Margherita |4 aut | |
| 700 | 1 | |a Giunti, Debora |4 aut | |
| 700 | 1 | |a Emanuela, Maria Mobilia |4 aut | |
| 700 | 1 | |a Visigalli, Davide |4 aut | |
| 700 | 1 | |a Capodivento, Giovanna |4 aut | |
| 700 | 1 | |a Cerne, Denise |4 aut | |
| 700 | 1 | |a Assini, Andrea |4 aut | |
| 700 | 1 | |a Boni, Silvia |4 aut | |
| 700 | 1 | |a Rizzi, Domenica |4 aut | |
| 700 | 1 | |a Narciso, Eleonora |4 aut | |
| 700 | 1 | |a Grisanti, Giuseppe Stefano |4 aut | |
| 700 | 1 | |a Coco, Elena |4 aut | |
| 700 | 1 | |a Uccelli, Antonio |4 aut | |
| 700 | 1 | |a Schenone, Angelo |4 aut | |
| 700 | 1 | |a Franciotta, Diego |4 aut | |
| 700 | 1 | |a Benedetti, Luana |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological sciences |d Milano : Springer, 2000 |g 45(2024), 3 vom: 03. Jan., Seite 849-859 |w (DE-627)SPR008581010 |w (DE-600)1481772-X |x 1590-3478 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g number:3 |g day:03 |g month:01 |g pages:849-859 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10072-023-07279-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |e 3 |b 03 |c 01 |h 849-859 | ||